Abstract
Despite advances in the treatment of refractory chronic hand eczema, many patients remain burdened with recalcitrant disease. Patients with limited therapeutic options may use topical bexarotene, systemic steroids, ranitidine, vitamin E, azathioprine, disulfiram, disodium cromoglycate, zinc sulfate, iron, or biologics to achieve control of symptoms. Evidence for the use of these atypical agents is only supported by smaller studies, anecdotal evidence, or single case reports.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83:841–50.
Cheng S, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:649–52.
Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol. 2004;150(3):545–53.
Alavi A, Skotnicki S, Sussman G, Sibbald RG. Diagnosis and treatment of hand dermatitis. Adv Skin Wound Care. 2012;8:381–2.
Warshaw E, Lee G, Storrs FJ. Hand dermatitis: a review of clinical features, therapeutic options, and long-term outcomes. Am J Contact Dermatol. 2003;14(3):119–37.
Nesbitt Jr LT. Minimizing complications from systemic glucocorticoid use. Dermatol Clin. 1995;13:925–39.
Nielsen HJ, Nielsen H, Georgsen J. Ranitidine for improvement of treatment resistant psoriasis: mechanisms and speculations. Dan Med Bull. 1991;38:478–80.
Veien NK, Kaaber K, Larsen PO, Nielsen AO, Thestrup-Pedersen K. Ranitidine treatment of hand eczema in patients with atopic dermatitis: a double blind placebo controlled trial. J Am Acad Dermatol. 1995;32:1056–7.
Olson PE, Torp EC, Mahon RT, Weiss PJ, Wallace MR. Oral vitamin E for refractory hand dermatitis. Lancet. 1994;343(8898):672–3.
Kappus H, Diplock AT. Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med. 1992;13:55–74.
Lakshmi C, Srinivas CR. Parthenium the terminator: an update. Indian Dermatol Online J. 2011;3:89–100.
Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, cross-over trial. Br J Dermatol. 2002;147:324–30.
Pearce VJ, Mortimer PS. Hand dermatitis and lymphoedema. Br J Dermatol. 2009;161(1):177–80.
Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol. 2001;26:369–75.
Christensen OB, Moller H. Nickel allergy and hand eczema. Contact Dermatitis. 1975;1:136–42.
Sharma AD. Disulfiram and low nickel diet in the management of hand eczema: a clinical study. Indian J Dermatol Venereol Leprol. 2006;72:113–8.
Kaaber K, Menne T, Tjell JC. Low nickel diet in the treatment of patients with chronic nickel dermatitis. Br J Dermatol. 1978;98:197.
Kaaber K, Menne T, Tjell JC, Veien N. Antabuse treatment of nickel dermatitis. Chelation- a new principal in the treatment of nickel dermatitis. Contact Dermatitis. 1979;5:221–8.
Kaaber K, Menne T, Veien N, Hougaard P. Treatment of nickel dermatitis with Antabuse; a double blind study. Contact Dermatitis. 1983;9:297–9.
Christensen OB, Kristensen M. Treatment with disulfiram in chronic nickel hand dermatitis. Contact Dermatitis. 1982;8:59–63.
Pigatto PD, Gibelli E, Fumagalli M, Bigardi A, Morelli M, Altomare GF. Disodium cromoglycate versus diet in the treatment and prevention of nickel-positive pompholyx. Contact Dermatitis. 1990;22:27–31.
Santucci B, Cristaudo A, Mehraban M, Valenzano C, Camera E, Picardo M. ZnSO4 treatment of NiSO4-positive patients. Contact Dermatitis. 1999;40:281–2.
Weissmann K, Menne T. Nickel allergy and drug interaction. In: Maibach HI, Menne T, editors. Nickel and the skin: immunology and toxicology. 1st ed. Boca Raton: CRC Press; 1989.
Sharma AD. Iron therapy in hand eczema: a new approach for management. Indian J Dermatol. 2011;56(3):295–9.
Tallkvist J, Bowlus CL, Lonnerdal B. Effect of iron treatment on nickel absorption and gene expression of the divalent metal transporter (DMT1) by human intestinal Caco-2 cells. Pharmacol Toxicol. 2003;92:121–4.
Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–22.
Ogden S, Clayton TH, Goodfield MJ. Recalcitrant hand pompholyx: variable response to etanercept. Clin Exp Dermatol. 2006;31(1):145–6.
Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345(4):248–55.
Gribetz GH, Blum R, Brady C, Cohen S, Lebwohi M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol. 2005;53:73–5.
Moed H, Boosma DM, Stoof TJ, von Blomberg BM, Bruynzeel DP, Scheper RJ, et al. Nickel-responding T cells are CD4+, CLA+, CD45RO45+ and express chemokine receptors CXCR3, CCR4, and CCRIO. Br J Dermalol. 2004;151:32–41.
Aronson PJ, Yeung-Yue KA. Treatment of hand dermatitis with alefacept. Dermatitis. 2008;19(3):161–2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Winkelmann, R.R., Alikhan, A. (2014). Systemic and Topical Treatment of Hand Eczema: Less Well-Established Agents. In: Alikhan, A., Lachapelle, JM., Maibach, H. (eds) Textbook of Hand Eczema. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39546-8_39
Download citation
DOI: https://doi.org/10.1007/978-3-642-39546-8_39
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-39545-1
Online ISBN: 978-3-642-39546-8
eBook Packages: MedicineMedicine (R0)